BIGBEAR
PHARMACEUTICALS
Lenvatinib blocks tumor angiogenesis and the signaling pathways for tumor cell proliferation, thereby exerting an anti-tumor effect.
AuthenticGuaranteeFast DeliveryPrivacy Approval AnnouncementWOODCLIFF LAKE, N.J., May 13, 2016 /PRNewswire/ -- Eisai Inc. announced that the U.S. Food and Drug Administration (FDA) has appr···【Read More】
Update: 13 Mar,2026Source: Haiou HealthViews: 71
Approval AnnouncementWoodcliff Lake, NJ and Kenilworth, NJ, Aug. 16, 2018 – Eisai Inc. and Merck (NYSE: MRK, known as MSD outside the U.S. and Canada)···【Read More】
Update: 13 Mar,2026Source: Haiou HealthViews: 69
Approval AnnouncementKENILWORTH, N.J., & WOODCLIFF LAKE, N.J.-- September 17, 2019 -- Merck (NYSE: MRK, known as MSD outside the U.S. and Canada) ···【Read More】
Update: 13 Mar,2026Source: Haiou HealthViews: 70
Approval OverviewAugust 11, 2021 — Merck (NYSE: MRK, known as MSD outside the U.S. and Canada) and Eisai announced the U.S. Food and Drug Administrati···【Read More】
Update: 13 Mar,2026Source: Haiou HealthViews: 71
FDA Approval AnnouncementKENILWORTH & WOODCLIFF, N.J.--(BUSINESS WIRE) July 22, 2021 -- Merck (NYSE: MRK, known as MSD outside the U.S. and Canada···【Read More】
Update: 12 Mar,2026Source: Haiou HealthViews: 71
Copyright2024@ BIGBEAR All right reserved BIGBEAR
